Heart surgery drug showdown: can vasopressin save more kidneys?
NCT ID NCT05568160
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares vasopressin to the standard drug noradrenaline for managing blood pressure after heart surgery. The goal is to see if vasopressin reduces the number of patients who develop acute kidney failure or die. About 840 adults having scheduled heart surgery with a heart-lung machine will participate, and they will be randomly assigned to receive one of the two drugs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vasopressin
- What this could lead to
- If vasopressin works better than noradrenaline, it could become a new standard to prevent kidney failure and reduce deaths after heart surgery.
- What could go wrong
- This is a large phase 3 trial, but results may not show a clear benefit over the current drug. Kidney protection is complex, and individual responses vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHEDULED CARDIAC SURGERY WITH EXTRACORPOREAL CIRCULATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chu Dijon Bourgogne
Dijon, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.